Elicera Therapeutics AB (publ) announced that the Data Safety and Monitoring Board (DSMB) completed its third assessment of the ongoing clinical phase I/IIa study with oncolytic virus, ELC-100, in neuroendocrine tumors and recommended continuation of the trial, as planned. The dose escalation study, which is carried out in collaboration with Uppsala University as sponsor, has previously been able to report signals of clinical activity in two of eight evaluable patients in the ELC-100 study, where a total of 12 patients are planned to be treated in four dose levels/cohorts. After the DSMB's recommendation to continue the trial, recruitment of the remaining three patients in the last cohort can commence.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.065 SEK | +8.67% | +13.30% | -76.64% |
03-28 | Elicera Therapeutics AB Announces Director Changes | CI |
03-06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.64% | 3.49M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- ELIC Stock
- News Elicera Therapeutics AB
- Elicera Therapeutics AB Continues Phase I/IIa Study with Oncolytic Virus as Planned, Following Safety Review in Cohort 3